Modifying influence of subclinical hypothyroidism on arterial hypertension: relationship to masked treatment failure, circadian blood pressure profile and target organs status
https://doi.org/10.14341/ket2015255-62
Abstract
About the Authors
T A NekrasovaL G Strongin
E P Morozova
E M Durigina
L V Kasakova
References
1. Бланкова З.Н., Серединина Е.М., Агеев Ф.Т. Влияние терапии левотироксином на клинический, гемодинамический и нейрогуморальный статус больных сердечной недостаточностью в сочетании с субклиническим гипотиреозом. // Журнал Сердечная Недостаточность. - 2011. - Т. 12. - №1 - C. 18-22. [Blankova ZN, Seredinina EM, Ageev FT. Vliyanie terapii levotiroksinom na klinicheskii, gemodinamicheskii i neirogumoral’nyi status bol’nykh serdechnoi nedostatochnost’yu v sochetanii s subklinicheskim gipotireozom. Zhurnal Serdechnaya Nedostatochnost’. 2011;12(1):18-22. (In Russ).]
2. Демидова Т.Ю., Галиева О.Р. К вопросу лечения субклинического гипотиреоза у больных ожирением. // Клиническая и экспериментальная тиреоидология. - 2008. - Т.4. - №1 - C. 48-52. [Demidova T, Galieva O. Treatment of subclinical hypothyroidism in obese patients. Clinical and experimental thyroidology. 2008;4(1):48-52. (In Russ).] doi: 10.14341/ket20084148-52.
3. Кравец Е.Б., Идрисова Е.М., Дамдиндорж Д., и др. Особенности суточного профиля артериального давления у больных с аутоиммунным тиреоидитом в фазе субклинического гипотиреоза. // Клиническая и экспериментальная тиреоидология. - 2008. - Т. 4. - №3 - С. 50-54. [Kravez EV, Idrisova EM, Damdindorsh D, et al. Daily rhythm of arterial pressure in patients with autoimmune thyroidite in a phase subclinical hypothyroidism. Clinical and experimental thyroidology. 2008;4(3):50-54. (In Russ).] doi: 10.14341/ket20084350-54.
4. Iqbal A, Figenschau Y, Jorde R. Blood pressure in relation to serum thyrotropin: The TROMSØ study. J Hum Hypertens. 2006;20(12): 932-936. doi: 10.1038/sj.jhh.1002091.
5. Ittermann T, Thamm M, Wallaschofski H, et al. Serum thyroid-stimulating hormone levels are associated with blood pressure in children and adolescents. J Clin Endocrinol Metab. 2012;97(3): 828-834. doi: 10.1210/jc.2011-2768.
6. Volzke H, Alte D, Dorr M, et al. The association between subclinical hyperthyroidism and blood pressure in a population-based study. J Hypertens. 2006;24(10):1947-1953. doi: 10.1097/01.hjh.0000244942.57417.8e.
7. Walsh JP, Bremner AP, Bulsara MK, et al. Subclinical thyroid dysfunction and blood pressure: A community-based study. Clin Endocrinol (Oxf). 2006;65(4):486-491. doi: 10.1111/j.1365-2265.2006.02619.x.
8. Килейников Д.В., Орлов Ю.А., Мазур В.В., и др. Влияние заместительной терапии на артериальную гипертензию и ремоделирование сердца у больных первичным гипотиреозом. // Клиническая и экспериментальная тиреоидология. - 2011. - Т. 7. - №1 - С. 41-44. [Kileinicov D, Orlov Y, Masur V, et al. Levothyroxine replacement therapy in patients with hypothyroidism, blood pressure and myocardial remodeling. Clinical and experimental thyroidology. 2011;7(1): 41-44. (In Russ).] doi: 10.14341/ket20117141-44.
9. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The task force for The management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). J Hypertens. 2013;31(7):1281-1357. doi: 10.1097/01.hjh.0000431740.32696.cc.
10. Кобалава Ж.Д., Котовская Ю.В. Артериальная гипертония в XXI веке: достижения, проблемы, перспективы. - М.: “Бионика Медиа”; 2013. [Kobalava ZD, Kotovskaya YV. Arterial’naya gipertoniya v XXI veke: dostizheniya, problemy, perspektivy. Moscow: “Bionika Media”; 2013. (In Russ).]
11. Горбунов В.М. Суточное мониторирование артериального давления: современные аспекты. - М.: “Логосфера”; 2015. [Gorbunov VM. Sutochnoe monitorirovanie arterial’nogo davleniya: sovremennye aspekty. Moscow: “Logosfera”; 2015. (In Russ).]
12. Pickering TG, Davidson K, Gerin W, et al. Masked hypertension. Hypertension. 2002;40(6):795-796. doi: 10.1161/01.hyp.0000038733.08436.98.
13. Bobrie G, Clerson P, Cuchet A, et al. Prevalence and mechanism of masked hypertension: The ol’mesures survey. Arch Mal Coeur Vaiss. 2006;99(7-8):760-763.
14. Bombelli M, Sega R, Facchetti R, et al. Prevalence and clinical significance of a greater ambulatory versus office blood pressure (’reversed white coat’ condition) in a general population. J Hypertens. 2005;23(3):513-520.
15. Mancia G, Facchetti R, Bombelli M, et al. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension. 2006;47(5):846-853. doi: 10.1161/01.HYP.0000215363.69793.bb.
16. Hansen TW, Jeppesen J, Rasmussen S, et al. Ambulatory blood pressure and mortality: A population-based study. Hypertension. 2005;45(4):499-504. doi: 10.1161/01.HYP.0000160402.39597.3b.
17. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: An updated meta analysis. Am J Hypertens. 2011;24(1):52-58. doi: 10.1038/ajh.2010.203.
18. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: A meta-analysis. J Hypertens. 2007;25(11):2193-2198. doi: 10.1097/HJH.0b013e3282ef6185.
19. Фадеев В.В. Заболевания щитовидной железы в регионе легкого йодного дефицита: эпидемиология, диагностика, лечение. - М.: “Видар”; 2005. [Fadeyev VV. Zabolevaniya shchitovidnoi zhelezy v regione legkogo iodnogo defitsita: epidemiologiya, diagnostika, lechenie. Moscow: “Vidar”; 2005. (In Russ).]
20. Parati G, Faini A, Valentini M. Blood pressure variability: Its measurement and significance in hypertension. Curr Hypertens Rep. 2006;8(3):199-204. doi: 10.1007/s11906-006-0051-6.
21. Sachdeva A, Weder AB. Nocturnal sodium excretion, blood pressure dipping, and sodium sensitivity. Hypertension. 2006;48(4): 527-533. doi: 10.1161/01.HYP.0000240268.37379.7c.
22. Stergiou GS, Parati G. How to best assess blood pressure?: The ongoing debate on the clinical value of blood pressure average and variability. Hypertension. 2011;57(6):1041-1042. doi: 10.1161/hypertensionaha.111.172924.
23. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. The Lancet. 2010;375(9718):938-948. doi: 10.1016/s0140-6736(10)60309-1.
24. Pearce SHS, Brabant G, Duntas LH, et al. 2013 eta guideline: Management of subclinical hypothyroidism. Eur Thyroid J. 2013;2(4):215-228. doi: 10.1159/000356507.
25. Cooper DS, Biondi B. Subclinical thyroid disease. The Lancet. 2012;379(9821):1142-1154. doi: 10.1016/s0140-6736(11)60276-6.
26. Rodondi N, Den Elzen WPJ, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304(12):1365. doi: 10.1001/jama.2010.1361.
27. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: Methodological issues and clinical applications. Eur Heart J. 2006;27(21):2588-2605. doi: 10.1093/eurheartj/ehl254.
Review
For citations:
Nekrasova T.A., Strongin L.G., Morozova E.P., Durigina E.M., Kasakova L.V. Modifying influence of subclinical hypothyroidism on arterial hypertension: relationship to masked treatment failure, circadian blood pressure profile and target organs status. Clinical and experimental thyroidology. 2015;11(2):55-62. (In Russ.) https://doi.org/10.14341/ket2015255-62

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).